BibTex format
@article{Berkes:2025:10.1097/aci.0000000000001077,
author = {Berkes, S and Liddell, K and Beyer, K and Blumchen, K and Deschildre, A and Kukkonen, K and Mäkelä, MJ and Patel, N and Turner, PJ},
doi = {10.1097/aci.0000000000001077},
journal = {Current Opinion in Allergy and Clinical Immunology},
pages = {185--193},
title = {Re-evaluating treatment success in trials of peanut oral-immunotherapy: impact of different definitions on efficacy outcomes},
url = {http://dx.doi.org/10.1097/aci.0000000000001077},
volume = {25},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Purpose of review Allergen immunotherapy (AIT) is increasingly popular as a treatment strategy for food allergy. Unfortunately, there is significant heterogeneity in reported outcomes, specifically in the dose-thresholds selected for evaluation and the symptoms used to define a “tolerated dose”. These considerations are often investigator-driven and do not consider patient perspectives.Recent findings A systematic review by the EAACI CO-FAITH taskforce recently flagged the need to better standardize and harmonize outcomes used in clinical trials of food-AIT. Using less objective symptoms to define dose-limiting symptoms can underestimate the reaction threshold determined at baseline food challenge. As a consequence, this can overestimate the efficacy of food-AIT by 15%. In this review, we perform an individual patient data (IPD) meta-analysis using data from three randomized-controlled trials and one real-world registry, to evaluate how the definition of dose “tolerance” impacts upon reported desensitization rates.Summary This analysis provides insight into how clinical efficacy rates for food-AIT are impacted by using different dose thresholds and definitions for when a dose might be consider tolerated. Using more patient-centric outcomes may be a more useful metric to harmonize reporting of outcomes and inform clinical practice, paving the way towards reaching a consensus on outcome reporting in trials of food-AIT.
AU - Berkes,S
AU - Liddell,K
AU - Beyer,K
AU - Blumchen,K
AU - Deschildre,A
AU - Kukkonen,K
AU - Mäkelä,MJ
AU - Patel,N
AU - Turner,PJ
DO - 10.1097/aci.0000000000001077
EP - 193
PY - 2025///
SN - 1473-6322
SP - 185
TI - Re-evaluating treatment success in trials of peanut oral-immunotherapy: impact of different definitions on efficacy outcomes
T2 - Current Opinion in Allergy and Clinical Immunology
UR - http://dx.doi.org/10.1097/aci.0000000000001077
UR - https://doi.org/10.1097/aci.0000000000001077
VL - 25
ER -